Puyin International: downgraded BeiGene A-share rating to 'hold', maintaining target price of 181 yuan
因醉鞭名马幌
发表于 2024-11-14 16:33:01
135
0
0
Caixin News Agency, November 14th - Puyin International released a research report, maintaining the "buy" rating of BeiGene (688235) on US and Hong Kong stocks, and adjusting the target prices of US and Hong Kong stocks to 255 US dollars and 153 Hong Kong dollars; Downgrading the A-share rating to 'hold' and maintaining the A-share target price of RMB 181.
In the third quarter of 2024, the company's performance was slightly lower than expected, but it achieved adjusted Non GAAP operating profit better than expected for two consecutive quarters: the total revenue of the company in the third quarter reached 1.002 billion US dollars (year-on-year+28.2%, month on month+7.8%), and the net loss was 121 million US dollars (year-on-year -156.3%, month on month+0.8%), which is basically in line with Visible Alpha expectations and lower than Puyin International's expectations, mainly due to slightly lower than expected gross profit margin and slightly higher than expected R&D expenses.
Zebutinib sales in the United States slowed down in the third quarter compared to the previous quarter, mainly due to seasonal factors and the impact of one-time drug purchases at the end of the second quarter, while sales in Europe continued to grow strongly.
The gross profit margin was temporarily affected by the depreciation of new production lines, and the sales management expense ratio further decreased. The R&D expense ratio in the third quarter was 496 million US dollars (year-on-year+9.5%, month on month+9.2%), with a slight increase compared to the second quarter, mainly due to continuous investment in R&D projects; The sales management expenses were $455 million, with an expense ratio of 45.4%, slightly lower than the second quarter (47.8%), reflecting higher operational efficiency. In the future, with the further expansion of revenue scale, we expect that there is still room for further decline in the sales management expense ratio.
In addition, BeiGene's research and development is progressing smoothly, and the next step of the pipeline will focus on BCL2, BTKCDAC, and CDK4 inhibitors.
In the end, Puyin International maintained BeiGene's "buy" rating on the US and Hong Kong stocks, and adjusted the target prices for the US and Hong Kong stocks to $255 and HKD 153; Downgrading the A-share rating to 'hold' and maintaining the A-share target price of 181 yuan.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- A senior executive of BeiGene has been investigated, and insiders say that the reason for the investigation is unrelated to BeiGene
- BeiGene executive Yin Min is suspected of smuggling and cooperating with the investigation
- Barclays raises Tesla target price from $220 to $235
- Morgan Stanley: Lowering AMD target price from $178 to $169
- Morgan Stanley: Lowering AMD target price from $178 to $169
- Barclays raises Chevron's target price from $168 to $174
- Huili Securities downgraded Tesla rating to selling target price of $230
- Goldman Sachs: Increases Bilibili's target price to HKD 180
- Barclays raises TSMC's target price from $215 to $240
- China International Capital Corporation (CICC) maintains its "outperform the industry" rating with a target price of $6.0
-
11月21日、2024世界インターネット大会烏鎮サミットで、創業者、CEOの周源氏が大会デジタル教育フォーラムとインターネット企業家フォーラムでそれぞれ講演、発言したことを知っている。周源氏によると、デジタル教 ...
- 不正经的工程师
- 3 小时前
- 支持
- 反对
- 回复
- 收藏
-
アリババは、26億5000万ドルのドル建て優先無担保手形と170億元の人民元建て優先無担保手形の定価を発表した。ドル債の発行は2024年11月26日に終了する予定です。人民元債券の発行は2024年11月28日に終了する予定だ ...
- SOGO
- 前天 09:05
- 支持
- 反对
- 回复
- 收藏
-
スターバックスが中国事業の株式売却の可能性を検討していることが明らかになった。 11月21日、外国メディアによると、スターバックスは中国事業の株式売却を検討している。関係者によると、スターバックスは中国事 ...
- 献世八宝掌
- 昨天 16:29
- 支持
- 反对
- 回复
- 收藏
-
【意法半導体CEO:中国市場は非常に重要で華虹と協力を展開】北京時間11月21日、意法半導体(STM.N)は投資家活動の現場で、同社が中国ウェハー代工場の華虹公司(688347.SH)と協力していると発表した。伊仏半導体 ...
- 黄俊琼
- 昨天 14:29
- 支持
- 反对
- 回复
- 收藏